The Evolving Treatment Landscape of Limited-Stage SCLC-Recording

Video Transcription

Video Summary

In a recent webinar, Dr. Bjorn-Hanning Gomberg discussed the evolving treatment landscape for limited-stage small cell lung cancer (SCLC), with a focus on recent advances in therapies. Traditionally, treatment for SCLC has been stage-based, divided into limited and extensive stages. Recent guidelines suggest considering surgery for very limited-stage disease in node-negative patients, which may include a lobectomy and lymph node dissection. Data suggest that surgery can be beneficial for certain patients compared to chemotherapy, though patient selection remains crucial.<br /><br />Dr. Gomberg highlighted various trials investigating the potential of systemic therapies, including chemotherapy and immunotherapy. Immunotherapy, while established for extensive-stage disease, is being explored in the adjuvant setting after surgery for limited-stage patients. However, challenges remain in establishing the most effective treatment schedules, particularly in integrating radiotherapy and novel therapies.<br /><br />The discussion emphasized the importance of careful patient selection for different therapeutic approaches and the potential of biomarkers in better identifying candidates for specific treatments. Furthermore, ongoing trials aim to clarify the role of prophylactic cranial irradiation (PCI) in both limited and extensive SCLC, especially in the context of integrated immunotherapy, given the potential cognitive side effects and the variability in patients' responses.<br /><br />In summary, the treatment of limited-stage SCLC is rapidly evolving with ongoing clinical trials exploring combinations of surgery, radiotherapy, chemotherapy, and immunotherapy. Better understanding through biomarkers and patient-centered approaches will likely enhance treatment personalization and improve outcomes.

Asset Subtitle

Dr. Jules Derks, MD, PhD
Dr. Daphne Dumoulin, MD, PhD
Dr. Bjørn Henning Grønberg, MD, PhD
Dr. Jeffrey Yang, MD

Keywords

small cell lung cancer

SCLC

limited-stage

immunotherapy

chemotherapy

surgery

biomarkers

radiotherapy

prophylactic cranial irradiation

treatment personalization